Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4498654 | 0.86 | ENPP2 (0.35) | AKR1C2AKR1C1NPC1RAB9AMAPK1 | |
| SCHEMBL4504457 | 0.85 | ENPP2 (0.42) | MAPK1 | |
| SCHEMBL4504228 | 0.83 | CRHR1 (0.37) | NPC1RAB9AMAPK1 | |
| SCHEMBL3242951 | 0.79 | MAPT (0.50) | LMNANPC1RAB9AMAPK1 | |
| SCHEMBL4493361 | 0.77 | ACHE (0.44) | NPC1RAB9A | |
| SCHEMBL4502225 | 0.74 | ENPP2 (0.35) | ADRB2MAPK1 | |
| SCHEMBL4492347 | 0.74 | ENPP2 (0.43) | NPC1RAB9A | |
| SCHEMBL4513405 | 0.70 | ENPP2 (0.34) | — | |
| SCHEMBL3240151 | 0.70 | SMN1; SMN2 (0.45) | LMNANPC1RAB9A | |
| SCHEMBL4502158 | 0.70 | ENPP2 (0.40) | LMNANPC1RAB9APOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | LMNA 3364/4885SIGMAR1 2299/4885TAAR1 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.